Industry Explorers Blaze On
Industry Explorers Blaze On is a series of interviews with senior executives who played a historical role in drug discovery and development and are still active in the biopharma industry.
Industry Explorers Blaze On: Anna Protopapas
Her mother was the first woman of her village in Cyprus to go to high school. Anna Protopapas shared her mother’s drive to bypass all barriers, and she now runs the biopharma company Mersana, after many years in the leadership of Millennium and Takeda.
Industry Explorers Blaze On: Pat Andrews
A look at the 26-year career of Pat Andrews, CEO of Boston Biomedical, who went from Big Pharma to small biotech.
Industry Explorers Blaze On: Deborah Dunsire
Deborah Dunsire has lived and worked in a world driven by commercial drug development for three decades. She’s worked for Big Pharmas such as Novartis and Sandoz and is now trying her hand at managing a small pharma as president & CEO of XTuit. For sure, she’s been a pioneer — but she’s not done yet.
Industry Explorers Blaze On: Leading Business With Science — Part 2
We continue the story of Geert Cauwenbergh whose nearly 40 years in the industry included work with Paul Janssen as well as being a startup entrepreneur with RXi Pharmaceuticals.
Leading Business With Science: Geert Cauwenbergh of RXi
Geert Cauwenbergh now can look back at his almost four decades in the industry — from his formative years working with Paul Janssen building a small company into a global phenomenon, to his later years as a startup entrepreneur with RXi — and reflect on how most of it has turned upon a snap decision.
Abbey Meyers: Did The Pioneer Of Orphan Drugs Spark Biopharma?
By the time Abbey Meyers, founder of the National Organization for Rare Disorders (NORD) and chief architect of the ODA, wrote her letter to me a few years later, the paradoxical conflict of orphan-drug availability versus price had become obvious.
David Hale: How The Journey To Entrepreneurial Biotech Begins
These are the stories of longtime leaders, still active in the industry, sharing their historical perspectives on innovation in the life sciences industry. This month: Why David Hale is considered an icon of entrepreneurial biotech.
Industry Explorers Blaze On: R&D Veteran William Comer Of NeuroGenetic
The chairman of Bristol-Myers summoned the head of R&D into his office. “Bill, go down and check out the ruckus on the street,” he said. “Something about our new AIDS drug.” When Dr. William Comer exited the front door of the company’s New York City headquarters, he saw a small group of men marching around on the sidewalk, holding signs, blowing trumpets, beating drums, and chanting loudly.
BEYOND THE PRINTED PAGE
9 Biopharma CEOs On COVID-19 Induced Trend Opportunities
This year’s CEO outlook article in Life Science Leader’s annual outlook issue, published in December, has 15 CEOs taking part! Some members of this year’s CEO class were posed a question around what COVID-19 induced trends they envisioned sticking around well beyond the end of this pandemic.
What COVID-19 Causations Will Continue In 2021 And Beyond?
Unprecedented. That’s the word used ad nauseam to describe much of what we experienced in 2020. And while many of these moves were unprecedented at the time, now that they’ve been done, they now serve as a precedent. This makes you wonder just how many COVID-19 causations will continue into 2021 and beyond?
Henri Termeer – A Much Missed Mentor
Chief Editor Rob Wright talks about the last time he spoke with Henri Termeer, who was a mentor to Paula Ragan, Ph.D., cofounder and CEO of X4 Pharmaceuticals (subject of the November 2020 cover feature in Life Science Leader).
LIFE SCIENCE LEADER BLOGS
What Would You Do?
A call with a young reader reveals a biopharmaceutical industry mentorship opportunity beyond science.
What Does Travel Look Like For You In 2021?
With the annual J.P. Morgan Healthcare conference going virtual in January of 2021, Rob Wright asks readers about their business travel plans for next year, and includes anonymized thoughts on posed questions from two Life Science Leader editorial advisory board members.